Diversified conglomerate Access Industries has led a $20.5m series B round for EIP Pharma, a US-based company developing treatments for diseases affecting the central nervous system (CNS).
Founded in 2014, EIP is working on drugs for CNS disorders, and in particular a small molecule inhibitor called neflamapimod that could potentially reverse the synaptic impairment associated with Alzheimer’s disease and improve the memory of patients.
The company will put the series B funding into advancing development of neflamapimod, which is set…
